Loading company…
Nectin Therapeutics is a Jerusalem biotechnology company developing next-generation immuno-oncology therapies for cancer patients.
Established in 2017 and based in Jerusalem, Israel, Nectin Therapeutics Ltd. develops immuno-oncology therapies for cancer patients. Its pipeline includes NTX1088, a first-in-class antibody for solid tumors, and NTX2R13, an antibody designed to target CD112R. In May 2024 the company raised USD 10 million in venture funding from the Guangzhou-Israel Biotechnology Fund. CEO Fabian Tenenbaum leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in